Could statins be a real therapeutic option for the treatment of hepatitis C?

We read with interest the recent article by malaguarnera et al. (1) on the reduction of non-alcoholic fatty liver disease (nafld) in patients receiving treatment for hepatitis c who were also treated with rosuvastatin. according to the results presented in the study, patients in the group receiving interferon, ribavirin, and rosuvastatin showed major improvements in their levels of aminotransferase, fasting glucose, insulin, and crp and their homa index. apparently, these parameters were predictors of sustained virological response (svr) in the univariate analysis, but not in the multivariate analysis. we believe that the design of the clinical trial was adequate to eliminate potential confounding factors. both groups were similar, and the liver tissue collected both before and after treatment allowed for an objective evaluation of steatosis in these patients.